Placeholder Banner

BIO letter to HHS Secretary Xavier Becerra on the importance of funding R&D for COVID-19 therapeutics at Biomedical Advanced Research and Development Agency (BARDA).

June 25, 2021

The partnership between the biopharmaceutical industry and the U.S. Government is largely responsible for where we are with the COVID-19 pandemic today. In just 16 months from the declaration of the pandemic, cases have dramatically dropped as more than 50% of U.S. adults have gotten vaccinated, and we now have proven treatments for cases of COVID-19. Despite this success, BIO and our members are concerned by the May 2021 change to the Biomedical Advanced Research and Development Agency (BARDA) Broad Agency Announcement (BAA) that suspends prioritization of Area of Interest (AOI) 9.2 -COVID-19 Therapeutics.

Download Full Comments Below
BIO letter to HHS Secretary Xavier Becerra on the importance of funding R&D for COVID-19 therapeutics at Biomedical Advanced Research and Development Agency (BARDA).
Discover More
COVID-19 will not be our last public health emergency.  We face numerous bio-threats from natural and bioterror threats.  Strong support for medical countermeasures R&D is critical to protecting our national security. Today I will…
The Biotechnology Innovation Organization (BIO) is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30…
Chairman Wyden, Ranking Member Crapo, Members of the Committee, my name is Dr. Michelle McMurry-Heath. I am the President and CEO of the Biotechnology Innovation Organization (BIO). I am honored to testify before you for today’s hearing,…